J Korean Pain Soc.  1988 Jun;1(1):64-73.

Effect of Epidural Morphine and Bupivacaine with Hypertonic Solution on the Duration of Analgesia

Affiliations
  • 1Department of Anesthesiology, School of Medicine, Soon Chun Hyang College, Seoul, Korea.
  • 2Department of Anesthesiology, Yonsei University, College of Medicine, Seoul, Korea.

Abstract

Recent studies have shown that narcotic drugs produc: an unusually intense, prolonged and aegmental analgesic action in man when injected into the spinal subarachnoid or epidural space (Wang et al, l979; Behar et al, 1979; Cousins et al, 1979. Magora et al, 1980, Johnston and McCaughey, 1980). Since 1960, many investigators claim d that low molecular weight (LMW) dextran increased the clinical duration of lidocaine (Loder, 1950; Loder, 1962), tetracaine (Chinn and Wirjoatmadja, 1967) and bupivacaine (Kaplan et al, 1975) in man but the mechanism of the action of dextran was unclear. But Curtiss and Scurlock (1979), and Buckley and Fink (1979) claimed that LMW dextran has no effect on the duration of action of bupivacaine in animal studies. The present study was performed to evaluate the clinical efficacy of analgesia by the thoracic epidural injection of morphine and bupivacaine mixture for the relief of pain due to fractured or contused ribs, to evaluate the duration of analgesic effect by the use of the above mixture in a hypertonic solution (dextran 70 or 50/ dextrose in water) and to observe the possibility of improvement in the lung function after the pain block. The complications following the pain block were also observed. The 50 single thoracic epidural injections of the mixture were divided into three groups: Group 1 (n = 15) served as a control group and drugs used for the relief of pain were as follows (Mean +/-S.D.): morphine (2.13 +/-1.64 mg), 0.5% bupivacaine (3.10 +/-l.04 ml) and 0.9% saline (3.64 +/- 1.11 ml). Group 2 (n=16) served as an experimental group and drugs were as follows (Mean +/- S.D.): morphine (2.13+0.72 mg), 0.5% bupivacaine (3.06 +/- 40.77 ml) and dextran 70 (3.75+1.29 ml), Group 3 (n = lg) served as an experimental group and drugs were as follows (Mean +/- S.D.): morphine (2.42 + 0.51 mg), 0.5% bupivacaine (3.21+0.71 ml) and 50% dextrose in water (3.68+1.11 ml). The results are were follows: 1) The number of patients who obtained excellent and good analgesic effects following the block were greater in the experimental Group 2 (94%) and Group 3 (90%) than those of the control Group 1 (80%). 2) The duration of pain relief which lasted more than 3 days after the epidural block was longer in the experimental Group 2 (81%) and Group 3 (75%) than those of the control Group 1 (67%). 3) The pulmonary reserve (FVC +/- FEV1.0%) of 27 cases who were treated by the pain block between 1 and 31 days following the cheat injury was increased to about 13% than those before the block, and that of 13 cases between 32 and 82 days following the chest injury was decreased to about 4% than those before the block. 4) Of the complications following the pain block, there were 5 cases (10%) of nausea within 3 hours following the block, 4 cases (8%) of vomiting after 2 hours following the block, 10 cases (20%) of pruritus after 3-4 hours following the block, 17 cases (34%) of transient urinary retention which lasted 8 to 19 hours, 3 cases (6%) of headache within 2 hours following the block and 2 cases (4%) of dural pancture. In conclusion, it is suggested that the cliaical duration of analgeaic effect produced by morphine and bupivacaine mixture can he prolonged by addition of the hypertonic solution to the mixture.


MeSH Terms

Analgesia*
Animals
Bupivacaine*
Dextrans
Epidural Space
Glucose
Headache
Humans
Injections, Epidural
Lidocaine
Lung
Molecular Weight
Morphine*
Nausea
Pruritus
Research Personnel
Ribs
Tetracaine
Thoracic Injuries
Urinary Retention
Vomiting
Water
Bupivacaine
Dextrans
Glucose
Lidocaine
Morphine
Tetracaine
Water
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr